Levonorgestrel-releasing intrauterine system: uses and controversies

References

• Luukkainen T. Levonorgestrel-releasing intrauterine device. Ann. NY Acad. Sci.626, 43–49 (1991).
   PubMedGoogle Scholar
• Luukkainen T. The levonorgestrel intrauterine system: therapeutic aspects. Steroids65(10–11), 699–702 (2000).
   PubMed Web of Science ®Google Scholar
• Faundes A, Alvarez F, Brache V, Tejada AS. The role of the levonorgestrel intrauterine device in the prevention and treatment of iron deficiency anemia during fertility regulation. Int. J. Gynaecol. Obstet.26(3), 429–433 (1988).
   PubMedGoogle Scholar
• Odlind V. Long-term experience of a levonorgestrel-releasing intrauterine system. Eur. J. Contracept. Reprod. Health Care1(4), 319–323 (1996).
   PubMedGoogle Scholar
• Hidalgo M, Bahamondes L, Perrotti M, Diaz J, Dantas-Monteiro C, Petta CA. Bleeding patterns and clinical performance of the levonorgestrel-releasing intrauterine system (Mirena) up to two years. Contraception65(2), 129–132 (2002).
   PubMed Web of Science ®Google Scholar
• Faúndes A, Alvarez F, Díaz J. A Latin American experience with levonorgestrel IUD. Ann. Med.25(2), 149–153 (1993).
   PubMed Web of Science ®Google Scholar
• Sivin I. Dose- and age-dependent ectopic pregnancy risks with intrauterine contraception. Obstet. Gynecol.78(2), 291–298 (1991).
   PubMed Web of Science ®Google Scholar
• Munuce MJ, Nascimento JAA, Rosano G, Faundes A, Bahamondes L. Doses of levonorgestrel comparable to that delivered by the levonorgestrel-releasing intrauterine system can modify the in vitro expression of zona binding sites of human spermatozoa. Contraception73(1), 97–101 (2006).
   PubMed Web of Science ®Google Scholar
• Sitruk-Ware R. Pharmacological profile of progestins. Maturitas47(4), 277–283 (2004).
   PubMed Web of Science ®Google Scholar
• Silverberg SG, Haukkamaa M, Arko H, Nilsson CG, Luukkainen T. Endometrial morphology during long-term use of levonorgestrel-releasing intrauterine devices. Int. J. Gynecol. Pathol.5(3), 235–241 (1986).
   PubMed Web of Science ®Google Scholar
• Guttinger A, Critchley HO. Endometrial effects of intrauterine levonorgestrel. Contrception75(6 Suppl.), S93–S98 (2007).
   Web of Science ®Google Scholar
• Peloggia A, Petta CA, Bahamondes L, Oliveira-Ribeiro M, Zhang J, Salamonsen L. Endometrial chemokines, uterine natural killer cells and mast cells in long-term users of the levonorgestrel-releasing intrauterine system. Hum. Reprod.21(5), 1129–1134 (2006).
   PubMed Web of Science ®Google Scholar
• Bahamondes L, Espejo-Arce X, Hidalgo MM, Hidalgo-Regina C, Teatin-Juliato C, Petta CA. A cross-sectional study of the forearm bone density of long-term users of levonorgestrel-releasing intrauterine system. Hum. Reprod.21(5), 1316–1319 (2006).
   PubMed Web of Science ®Google Scholar
• Bahamondes L, Hidalgo M, Petta CA, Diaz J, Espejo-Arce X, Monteiro-Dantas C. Enlarged ovarian follicles in users of a levonorgestrel-releasing intrauterine system and contraceptive implant. J. Reprod. Med.48(8), 637–640 (2003).
   PubMed Web of Science ®Google Scholar
• Inki P, Hurskainen R, Palo P et al. Comparison of ovarian cyst formation in women using the levonorgestrel-releasing intrauterine system vs. hysterectomy. Ultrasound Obstet. Gynecol.20(4), 381–385 (2002).
   PubMed Web of Science ®Google Scholar
• Rogovskaya S, Rivera R, Grimes DA et al. Effect of a levonorgestrel intrauterine system on women with Type 1 diabetes: a randomized trial. Obstet. Gynecol.105(4), 811–815 (2005).
   PubMed Web of Science ®Google Scholar
• Koh SC, Singh K. The effect of levonorgestrel-releasing intrauterine system use on menstrual blood loss and the hemostatic, fibrinolytic/inhibitor systems in women with menorrhagia. J. Thromb. Haemost.5(1), 133–138 (2007).
   PubMed Web of Science ®Google Scholar
• Graff-Iversen S, Tonstad S. Use of progestogen-only contraceptives/medications and lipid parameters in women age 40 to 42 years: results of a population-based cross-sectional Norwegian survey. Contraception66(1), 7–13 (2002).
   PubMed Web of Science ®Google Scholar
• Rönnerdag M, Odlind V. Health effects of long-term use of the intrauterine levonorgestrel-releasing system. A follow-up study over 12 years of continuous use. Acta Obstet. Gynecol. Scand.78(8), 716–721 (1999).
   PubMed Web of Science ®Google Scholar
• Yela DA, Monteiro IM, Bahamondes LG, Del Castillo S, Bahamondes MV, Fernandes A. Weight variation in users of the levonorgestrel-releasing intrauterine system, of the copper IUD and of medroxyprogesterone acetate in Brazil. Rev. Assoc. Med. Bras.52(1), 32–36 (2006).
   PubMedGoogle Scholar
• Lessard T, Simons JA, Discacciati MG, Hidalgo M, Bahamondes L. Cytological evaluation and investigation of the vaginal flora of long-term users of the levonorgestrel-releasing intrauterine system (LNG-IUS). Contraception77(1), 30–33 (2008).
   PubMed Web of Science ®Google Scholar
• Misra JS, Engineer AD, Tandon P. Cervical cytology associated with levonorgestrel contraception. Acta Cytol.39(1), 45–49 (1995).
   PubMedGoogle Scholar
• Toivonen J, Luukkainen T, Allonen H. Protective effect of intrauterine release of levonorgestrel on pelvic infection: three years’ comparative experience of levonorgestrel- and copper-releasing intrauterine devices. Obstet. Gynecol.77(2), 261–264 (1991).
   PubMed Web of Science ®Google Scholar
• Sivin I, Stern J, Coutinho E et al. Prolonged intrauterine contraception: a seven-year randomized study of the levonorgestrel 20 mcg/day (LNg 20) and the Copper T380 Ag IUDS. Contraception44(5), 473–480 (1991).
   PubMed Web of Science ®Google Scholar
• Baveja R, Bichille LK, Coyaji KJ et al. Randomized clinical trial with intrauterine devices (levonorgestrel intrauterine device (LNG), CuT 380Ag, CuT 220C and CuT 200B). A 36 -month study. Indian Council of Medical Research Task Force on IUD. Contraception39(1), 37–52 (1989).
   PubMedGoogle Scholar
• Haukkamaa M, Stranden P, Jousimies-Somer H, Siitonen A. Bacterial flora of the cervix in women using different methods of contraception. Am. J. Obstet. Gynecol.154(3), 520–524 (1986).
   PubMed Web of Science ®Google Scholar
• Heikkilä M, Haukkamaa M, Luukkainen T. Levonorgestrel in milk and plasma of breast-feeding women with a levonorgestrel-releasing IUD. Contraception25(1), 41–49 (1982).
   PubMed Web of Science ®Google Scholar
• Heikkilä M, Luukkainen T. Duration of breast-feeding and development of children after insertion of a levonorgestrel-releasing intrauterine contraceptive device. Contraception25(3), 279–292 (1982).
   PubMed Web of Science ®Google Scholar
• Ortayli N, Bulut A, Sahin T, Sivin I. Immediate postabortal contraception with the levonorgestrel intrauterine device, Norplant, and traditional methods. Contraception63(6), 309–314 (2001).
   PubMedGoogle Scholar
• Pakarinen P, Toivonen J, Luukkainen T. Randomized comparison of levonorgestrel- and copper-releasing intrauterine systems immediately after abortion, with 5 years’ follow-up. Contraception68(1), 31–34 (2003).
   PubMed Web of Science ®Google Scholar
• Pakarinen P, Toivonen J, Luukkainen T. Therapeutic use of the LNG IUS, and counseling. Semin. Reprod. Med.19(4), 365–372 (2001).
   PubMed Web of Science ®Google Scholar
• Luukkainen T, Allonen H, Haukkamaa M et al. Effective contraception with the levonorgestrel-releasing intrauterine device: 12-month report of a European multicenter study. Contraception36(2), 169–179 (1987).
   PubMed Web of Science ®Google Scholar
• Andersson K, Odlind V, Rybo G. Levonorgestrel-releasing and copper-releasing (Nova T) IUDs during five years of use: a randomized comparative trial. Contraception49(1), 56–72 (1994).
   PubMed Web of Science ®Google Scholar
• Backman T, Rauramo I, Huhtala S, Koskenvuo M. Pregnancy during the use of levonorgestrel intrauterine system. Am. J. Obstet. Gynecol.190(1), 50–54 (2004).
   PubMed Web of Science ®Google Scholar
• Peterson HB, Xia Z, Hughes JM, Wilcox LS, Tylor LR, Trussell J. The risk of pregnancy after tubal sterilization: findings from the U.S. Collaborative Review of Sterilization. Am. J. Obstet. Gynecol.174(4), 1161–1168 (1996).
   PubMed Web of Science ®Google Scholar
• Sivin I, Stern J. Health during prolonged use of levonorgestrel 20 micrograms/d and the copper TCu 380Ag intrauterine contraceptive devices: a multicenter study. International Committee for Contraception Research (ICCR). Fertil. Steril.61(1), 70–77 (1994).
   PubMed Web of Science ®Google Scholar
• Andersson K, Batar I, Rybo G. Return to fertility after removal of a levonorgestrel-releasing intrauterine device and Nova-T. Contraception46(6), 575–584 (1992).
   PubMed Web of Science ®Google Scholar
• Reid PC, Coker A, Coltart R. Assessment of menstrual blood loss using a pictorial chart: a validation study. Br. J. Obstet. Gynecol.107(3), 320–322 (2000).
   Google Scholar
• Monteiro I, Bahamondes L, Diaz J, Perrotti M, Petta C. Therapeutic use of levonorgestrel-releasing intrauterine system in women with menorrhagia: a pilot study. Contraception65(5), 325–328 (2002).
   PubMedGoogle Scholar
• Andersson JK, Rybo G. Levonorgestrel-releasing intrauterine device in the treatment of menorrhagia. Br. J. Obstet. Gynecol.97(8), 690–694 (1990).
   PubMedGoogle Scholar
• Milsom I, Andersson K, Andersch B, Rybo G. A comparison of flurbiprofen, tranexamic acid, and a levonorgestrel-releasing intrauterine contraceptive device in the treatment of idiopathic menorrhagia. Am. J. Obstet. Gynecol.164(3), 879–883 (1991).
   PubMed Web of Science ®Google Scholar
• Irvine GA, Campbell-Brown MB, Lumsden MA, Heikkila A, Walker JJ, Cameron IT. Randomised comparative trial of the levonorgestrel intrauterine system and norethisterone for treatment of idiopathic menorrhagia. Br. J. Obstet. Gynecol.105(6), 592–598 (1998).
   PubMedGoogle Scholar
• Reid PC, Virtanen-Kari S. Randomized comparative trial of the levonorgestrel intrauterine system and mefenamic acid for the treatment of idiopathic menorrhagia: a multiple analysis using total menstrual fluid loss, menstrual blood loss and pictorial blood loss assessment charts. Br. J. Obstet. Gynecol.112(8), 1121–1125 (2005).
   Google Scholar
• Lähteenmäki P, Haukkamaa M, Puolakka J et al. Open randomised study of use of levonorgestrel releasing intrauterine system as alternative to hysterectomy. Br. Med. J.316(7138), 1122–1126 (1998).
   PubMed Web of Science ®Google Scholar
• Barrington JW, Arunkalaivanan AS, Abdel-Fattah M. Comparison between the levonorgestrel intrauterine system (LNG-IUS) and thermal balloon ablation in the treatment of menorrhagia. Eur. J. Obstet. Gynecol. Reprod. Biol.108(1), 72–74 (2003).
   PubMed Web of Science ®Google Scholar
• Busfield RA, Farquhar CM, Sowter MC et al. A randomised trial comparing the levonorgestrel intrauterine system and thermal balloon ablation for heavy menstrual bleeding. Br. J. Obstet. Gynecol.113(3), 257–263 (2006).
   Google Scholar
• Brown PM, Farquhar CM, Lethaby A, Sadler LC, Johnson NP. Cost–effectiveness analysis of levonorgestrel intrauterine system and thermal balloon ablation for heavy menstrual bleeding. Br. J. Obstet. Gynecol.113(7), 797–803 (2006).
   Google Scholar
• Istre O, Trolle B. Treatment of menorrhagia with the levonorgestrel intrauterine system versus endometrial resection. Fertil. Steril.76(2), 304–309 (2001).
   PubMed Web of Science ®Google Scholar
• Hurskainen R, Teperi J, Rissanen P et al. Quality of life and cost–effectiveness of levonorgestrel-releasing intrauterine system versus hysterectomy for treatment of menorrhagia: a randomised trial. Lancet357(9252), 273–277 (2001).
   PubMed Web of Science ®Google Scholar
• Hurskainen R, Teperi J, Rissanen P et al. Clinical outcomes and costs with the levonorgestrel-releasing intrauterine system or hysterectomy for treatment of menorrhagia: randomized trial 5-year follow-up. JAMA291(12), 1456–1463 (2004).
   PubMed Web of Science ®Google Scholar
• Sitruk-Ware R, Inki P. The levonorgestrel intrauterine system: long-term contraception and therapeutic effects. Women Health1(2), 171–182 (2005).
   PubMedGoogle Scholar
• Sitruk-Ware R. The levonorgestrel intrauterine system for use in peri- and postmenopausal women. Contraception75(Suppl. 1), S155–S160 (2007).
   PubMed Web of Science ®Google Scholar
• Riphagen FE. Intrauterine application of progestins in hormone replacement therapy: a review. Climacteric3(3), 199–211 (2000).
   PubMedGoogle Scholar
• Suhonen S, Holmström T, Lähteenmäki P. Three-year follow-up of the use of a levonorgestrel-releasing intrauterine system in hormone replacement therapy. Acta Obstet. Gynecol. Scand.76(2), 145–150 (1997).
   PubMed Web of Science ®Google Scholar
• Andersson K, Rybo G, Mattsson LO, Stadberg E. Intrauterine release of levonorgestrel – a new way of adding progestogen in hormone replacement therapy. Obstet. Gynecol.79(6), 963–967 (1992).
   PubMed Web of Science ®Google Scholar
• Raudaskoski TH, Lahti EI, Kauppila AJ, Apaja-Sarkkinen MA, Laatikainen TJ. Transdermal estrogen with a levonorgestrel-releasing intrauterine device for climacteric complaints: clinical and endometrial responses. Am. J. Obstet. Gynecol.172(1 Pt 1), 114–119 (1995).
   PubMed Web of Science ®Google Scholar
• Suhonen S, Allonen H, Lähteenmäki P. Sustained-release estradiol implants and a levonorgestrel-releasing intrauterine device in hormone replacement therapy. Am. J. Obstet. Gynecol.172(2 Pt 1), 562–567 (1995).
   PubMed Web of Science ®Google Scholar
• Varila E, Wahlstrom T, Rauramo I. A 5-year follow-up study on the use of a levonorgestrel intrauterine system in women receiving hormone replacement therapy. Fertil. Steril.76(5), 769–773 (2001).
   PubMedGoogle Scholar
• Suvanto-Luukkonen E, Kauppila A. The slevonorgestrel intrauterine system in menopausal hormone replacement therapy: five-year experience. Fertil. Steril.72(1), 161–163 (1999).
   PubMed Web of Science ®Google Scholar
• Hampton NR, Rees MC, Lowe DG, Rauramo I, Barlow D, Guillebaud J. Levonorgestrel intrauterine system (LNG-IUS) with conjugated oral equine estrogen: a successful regimen for HRT in perimenopausal women. Hum. Reprod.20(9), 2653–2660 (2005).
   PubMed Web of Science ®Google Scholar
• Blumenfeld Z, Boulman N, Leiba R, Siegler E, Shachar S, Linn R, Levy Y. High C-reactive protein levels are associated with oral hormonal menopausal therapy but not with intrauterine levonorgestrel and transdermal estradiol. Scand. J. Clin. Lab. Invest.67(3), 257–263 (2007).
   PubMed Web of Science ®Google Scholar
• Prentice A, Deary AJ, Goldbeck-Wood S, Farquhar C, Smith SK. Gonadotrophin-releasing hormone analogues for pain associated with endometriosis. Cochrane Database Syst. Rev.2, CD000346 (2000).
   Google Scholar
• Fedele L, Berlanda N. Emerging drugs for endometriosis. Expert Opin. Emerg. Drugs9(1), 167–177 (2004).
   PubMedGoogle Scholar
• Vercellini P, Aimi G, Panazza S, De Giorgi O, Pesole A, Crosignani PG. A levonorgestrel-releasing intrauterine system for the treatment of dysmenorrhea associated with endometriosis: a pilot study. Fertil. Steril.72(3), 505–508 (1999).
   PubMed Web of Science ®Google Scholar
• Vercellini P, Frontino G, De Giorgi O, Aimi G, Zaina B, Crosignani PG. Comparison of a levonorgestrel-releasing intrauterine device versus expectant management after conservative surgery for symptomatic endometriosis: a pilot study. Fertil. Steril.80(2), 305–309 (2003).
   PubMed Web of Science ®Google Scholar
• Fedele L, Bianchi S, Zanconato G, Portuese A, Raffaelli R. Use of a levonorgestrel-releasing intrauterine device in the treatment of rectovaginal endometriosis. Fertil. Steril.75(3), 485–488 (2001).
   PubMed Web of Science ®Google Scholar
• Petta CA, Ferriani RA, Abrão MS et al. Randomized clinical trial of a levonorgestrel-releasing intrauterine system and a depot GnRH analogue for the treatment of chronic pelvic pain in women with endometriosis. Hum. Reprod.20(7), 1993–1998 (2005).
   PubMed Web of Science ®Google Scholar
• Lockhat FB, Emembolu JO, Konje JC. The evaluation of the effectiveness of an intrauterine-administered progestogen (levonorgestrel) in the symptomatic treatment of endometriosis and in the staging of the disease. Hum. Reprod.19(1), 179–184 (2004).
   PubMed Web of Science ®Google Scholar
• Lockhat FB, Emembolu JO, Konje JC. The efficacy, side effects and continuation rates in women with symptomatic endometriosis undergoing treatment with an intra-uterine administered progestogen (levonorgestrel): a 3 year follow-up. Hum. Reprod.20(3), 789–793 (2005).
   PubMed Web of Science ®Google Scholar
• Bragheto AM, Caserta N, Bahamondes L, Petta CA. Effectiveness of the levonorgestrel-releasing intrauterine system in the treatment of adenomyosis diagnosed and monitored by magnetic resonance imaging. Contraception76(3), 195–199 (2007).
   PubMed Web of Science ®Google Scholar
• Scarselli G, Tantini C, Colafranceschi M et al. Levo-norgestrel-nova-T and precancerous lesions of the endometrium. Eur. J. Gynaecol. Oncol.9(4), 284–286 (1988).
   PubMedGoogle Scholar
• Montz FJ, Bristow RE, Bovicelli A, Tomacruz R, Kurman RJ. Intrauterine progesterone treatment of early endometrial cancer. Am. J. Obstet. Gynecol.186(4), 651–657 (2002).
   PubMed Web of Science ®Google Scholar
• Bahamondes L, Ribeiro-Huguet P, de Andrade KC, Leon-Martins O, Petta CA. Levonorgestrel-releasing intrauterine system (Mirena) as a therapy for endometrial hyperplasia and carcinoma. Acta Obstet. Gynecol. Scand.82(6), 580–582 (2003).
   PubMed Web of Science ®Google Scholar
• Giannopoulos T, Butler-Manuel S, Tailor A. Levonorgestrel-releasing intrauterine system (LNG-IUS) as a therapy for endometrial carcinoma. Gynecol. Oncol.95(3), 762–764 (2004).
   PubMed Web of Science ®Google Scholar
• Dhar KK, NeedhiRajan T, Koslowski M, Woolas RP. Is levonorgestrel intrauterine system effective for treatment of early endometrial cancer? Report of four cases and review of the literature. Gynecol. Oncol.97(3), 924–927 (2005).
   PubMed Web of Science ®Google Scholar
• Vereide AB, Arnes M, Straume B, Maltau JM, Ørbo A. Nuclear morphometric changes and therapy monitoring in patients with endometrial hyperplasia: a study comparing effects of intrauterine levonorgestrel and systemic medroxyprogesterone. Gynecol. Oncol.91(3), 526–533 (2003).
   PubMed Web of Science ®Google Scholar
• Gardner FJ, Konje JC, Abrams KR et al. Endometrial protection from tamoxifen-stimulated changes by a levonorgestrel-releasing intrauterine system: a randomized controlled trial. Lancet356(9243), 1711–1717 (2000).
   PubMed Web of Science ®Google Scholar
• Chan SS, Tam WH, Yeo W et al. A randomised controlled trial of prophylactic levonorgestrel intrauterine system in tamoxifen-treated women. Br. J. Obstet. Gynecol.114(12), 1510–1515 (2007).
   Google Scholar
• Rodeghiero F, Castaman G, Dini E. Epidemiological investigation of the prevalence of von Willebrand’s disease. Blood69(2), 454–459 (1987).
   PubMed Web of Science ®Google Scholar
• Foster PA. The reproductive health of women with von Willebrand disease unresponsive to DDAVP; results of an international survey. Thromb. Haemost.74(2), 784–790 (1995).
   PubMedGoogle Scholar
• Kingman CE, Kadir RA, Lee CA, Economides DL. The use of levonorgestrel-releasing intrauterine system for treatment of menorrhagia in women with inherited bleeding disorders. Br. J. Obstet. Gynecol.111(12), 1425–1428 (2004).
   Google Scholar
• Lukes AS, Reardon B, Arepally G. Use of the levonorgestrel-releasing intrauterine system in women with hemostatic disorders. Fertil. Steril. (2007) (Epub ahead of print).
   Google Scholar
• Schaedel ZE, Dolan G, Powell M. The use of the levonorgestrel-releasing intrauterine system in the management of menorrhagia in women with hemostatic disorders. Am. J. Obstet. Gynecol.193(4), 1361–1363 (2005).
   PubMed Web of Science ®Google Scholar
• Pisoni CN, Cuadrado MJ, Khamashta MA, Hunt BJ. Treatment of menorrhagia associated with oral anticoagulation: efficacy and safety of the levonorgestrel releasing intrauterine device (Mirena coil). Lupus15(12), 877–880 (2006).
   PubMed Web of Science ®Google Scholar
• da Silveira Rossi A, Fonsechi-Carvasan GA, Makuch MY, Amaral E, Bahamondes L. Factors associated with reproductive options in HIV-infected women. Contraception71(1), 45–50 (2005).
   PubMed Web of Science ®Google Scholar
• Heikinheimo O, Lehtovirta P, Suni J, Paavonen J. The levonorgestrel-releasing intrauterine system (LNG-IUS) in HIV-infected women – effects on bleeding patterns, ovarian function and genital shedding of HIV. Hum. Reprod.21(11), 2857–2861 (2006).
   PubMed Web of Science ®Google Scholar
• Mercorio F, De Simone R, Di Spiezio Sardo A et al. The effect of levonorgestrel-releasing intrauterine device in the treatment of myoma-related menorrhagia. Contraception67(4), 277–280 (2003).
   PubMed Web of Science ®Google Scholar
• Grigorieva V, Chen-Mok M, Tarasova M, Mikhailov A. Use of a levonorgestrel-releasing intrauterine system to treat bleeding related to uterine leiomyomas. Fertil. Steril.79(5), 1194–1198 (2003).
   PubMed Web of Science ®Google Scholar
• Soysal S, Soysal M. The efficacy of levonorgestrel-releasing intrauterine device in selected cases of myoma-related menorrhagia: a prospective controlled trial. Gynecol. Obstet. Invest.59(1), 29–35 (2005).
   PubMed Web of Science ®Google Scholar
• Magalhães J, Aldrighi JM, de Lima GR. Uterine volume and menstrual patterns in users of the levonorgestrel-releasing intrauterine system with idiopathic menorrhagia or menorrhagia due to leiomyomas. Contraception75(3), 193–198 (2007).
   PubMed Web of Science ®Google Scholar
• Mattinson A, Mansour D. Female sterilization: is it what women really want or are alternative contraceptive methods acceptable? J. Fam. Plann. Reprod. Health Care32(3), 181–183 (2006).
   PubMedGoogle Scholar
• Mansour D. Copper IUD and LNG IUS compared with tubal occlusion. Contraception75(6 Suppl.), S144–S151 (2007).
   PubMed Web of Science ®Google Scholar
• Reid PC, Mukri F. Trends in number of hysterectomies performed in England for menorrhagia: examination of health episode statistics, 1989 to 2002–3. Br. Med. J.330(7497), 938–939 (2005).
   PubMed Web of Science ®Google Scholar
• Raudaskoski T, Tapanainen J, Tomas E et al. Intrauterine 10 µg and 20 µg levonorgestrel systems in postmenopausal women receiving oral oestrogen replacement therapy: clinical, endometrial and metabolic response. Br. J. Obstet. Gynecol.109(2), 136–144 (2002).
   Google Scholar
• Pakarinen P. Luukkainen T. Five years’ experience with a small intracervical/intrauterine levonorgestrel-releasing device. Contraception72(5), 342–345 (2005).
   PubMed Web of Science ®Google Scholar
• Rossouw JE, Anderson GL, Prentice RL et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA288(3), 321–333 (2002).
   PubMed Web of Science ®Google Scholar
• Banks E, Reeves G, Beral V et al. Impact of use of hormone replacement therapy on false positive recall in the NHS breast screening programme: results from the Million Women Study. Br. Med. J.328(7451), 1291–1292 (2004).
   PubMedGoogle Scholar
• Backman T, Rauramo I, Jaakkola K et al. Use of the levonorgestrel-releasing intrauterine system and breast cancer. Obstet. Gynecol.106(4), 813–817 (2005).
   PubMed Web of Science ®Google Scholar
• Kaunitz A. Progestin-releasing intrauterine systems and leiomyoma. Contraception75(Suppl. 1), S130–S133 (2007).
   PubMed Web of Science ®Google Scholar